Medical Devices - Women's Reproductive Health & Fertility
Strategic Profile
Femasys is expanding its European commercial footprint through distribution agreements and has expanded market entry in Spain, France, Switzerland and the Benelux region. The company achieved FDA IDE approval and FDA 510(k) clearance for next-generation FemVue device, with commercial progress including financing with potential proceeds up to $58 million.
Cyborg Score Rationale
Femasys received a 180-day extension from Nasdaq on January 13, 2026 to regain compliance with the minimum $1.00 bid price requirement by July 13, 2026. While the company shows strong clinical and regulatory progress, it faces significant liquidity challenges reflected in its depressed stock price. The company may need a reverse stock split to maintain listing compliance.
Top Insights
Achieved FDA IDE approval and financing with potential proceeds up to $58 million in November 2025.
Aggressively expanding European commercial footprint with distribution agreements across multiple countries including Switzerland, France, Spain and Benelux region.
Under Nasdaq compliance watch with deadline of July 13, 2026 to achieve minimum $1.00 closing bid price.
Revenue grew 52% YoY to $1.63 million in 2024, but net losses increased to $18.82 million.
Named Competitors
Fertility and Contraception Devices — Established players in women's reproductive health and fertility diagnostics
Intratubal Insemination — Competitor in fertility treatment solutions
Non-surgical Contraception — Established contraception device manufacturers
Recent Developments
(January 2026) Nasdaq granted 180-day extension to regain bid price compliance by July 13, 2026
(December 2025) FDA 510(k) clearance for next-generation FemVue device
(November 2025) FDA IDE approval for FemBloc and $58M financing arrangement; $500K European FemBloc order
(January 2026) Partnership with Refuah Health Center to expand FemaSeed access in community-based care
Open the full interactive Femasys Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.